Red yeast rice has been sold as a cholesterol supplement for decades, and for most of that time the European Union agreed it worked. There was an authorised health claim on the books saying so.
That claim is now gone, and the ingredient behind it sits under a restriction that caps how much can go in a daily portion and requires four separate warnings on the label.
Nothing about the ingredient changed. What changed was that a regulator looked closely at what monacolin K actually is, and the answer turned out to be uncomfortable. This is the sequence, with the primary texts linked at the end.
First, what monacolin K is
Red yeast rice is rice fermented with the mould *Monascus purpureus*. That fermentation produces a family of compounds called monacolins, and the one that matters here is monacolin K.
In its lactone form, monacolin K is identical to lovastatin — the active ingredient of prescription medicines authorised in the EU to treat high cholesterol. That is not my comparison. It is the finding of the EFSA panel that assessed it[1].
This is where I had to adjust my own thinking. I had filed red yeast rice under “natural alternative to a statin,” which quietly implies it is something different in kind. It is not a different kind of thing. It is the same molecule, arriving in a food supplement rather than a prescription.
2018: EFSA assessed the safety, not the benefit
In 2018, EFSA’s panel on food additives and nutrient sources published a safety opinion on monacolins in red yeast rice. The question put to it was narrow: is there a daily intake that does not raise health concerns?
The panel’s findings were blunt. Intake from food supplements could reach exposures within the range of therapeutic lovastatin doses[1]. At a use level of 10 mg/day, monacolins from red yeast rice were judged to be of significant safety concern[1]. Individual cases of severe adverse reactions had been reported at intakes as low as 3 mg/day[1].
The effects at issue were not mild. The opinion names severe effects on the musculoskeletal system, including rhabdomyolysis — a breakdown of muscle tissue that can damage the kidneys — and on the liver[1].
And the conclusion was the one that drives everything afterwards: the panel was unable to identify any dietary intake of monacolins from red yeast rice that does not give rise to concerns, for the general population or for vulnerable subgroups[1].
A regulator can work with “safe below X.” It cannot do much with “we cannot find an X.”
2022: what the restriction actually says
The Commission acted on that opinion in Commission Regulation (EU) 2022/860, which entered into force on 22 June 2022[2].
Two things happened at once. Products may now only provide less than 3 mg of monacolins from red yeast rice per daily portion — at 3 mg and above they are prohibited. And monacolins were simultaneously placed under Union scrutiny, a holding status that invites interested parties to submit data showing the substance is safe[2].
The regulation also requires the label to carry four warnings, and reading them together tells you how the EU understands this ingredient.
[Table 1] The warnings an EU red yeast rice label must carry · Source: Commission Regulation (EU) 2022/860[2]
| Required warning |
| Not for pregnant or lactating women, children under 18, or adults over 70 |
| Seek advice from a doctor if you experience any health problems |
| Not to be consumed if you are taking cholesterol-lowering medication |
| Not to be consumed alongside other products containing red yeast rice |
Labels must also declare the monacolin content per portion and the number of portions for maximum daily consumption[2].
Look at the third line. A supplement that tells you not to combine it with cholesterol medication is a supplement being treated as cholesterol medication.
2024 and 2025: the claim goes, the scrutiny closes
Here the story turns, because for years the EU held two positions at once: monacolin K was restricted as a safety matter, and simultaneously carried an authorised claim that it helps maintain normal LDL-cholesterol.
That ended on 29 July 2024. Commission Regulation (EU) 2024/2041 deleted the *Monascus purpureus* entry from the Union list of permitted health claims outright[3]. The stated reasoning was that because no daily intake without health concerns could be set, the claim could not stand[3].
Then in February 2025, EFSA reported on the data submitted during the scrutiny period — analytical data, intake estimates, post-marketing surveillance, case reports and clinical studies. The panel reiterated that exposure at levels as low as 3 mg/day could lead to severe musculoskeletal and liver effects. It concluded that the submitted data do not allow establishing the safety of monacolins below 3 mg/day, nor identifying any intake that does not raise concerns[4].
So the industry was given a defined opportunity to show safety under the current limit, and in EFSA’s assessment did not.
How the EU position moved, 2018 to 2025
The ingredient did not change. The assessment of what it is did.
Note — EU law is amended over time. Check the current consolidated text on EUR-Lex before relying on a figure.
One caution on all of this. I verified each step against the primary text as of writing, and EU law moves. Before relying on a specific figure, check the current consolidated version on EUR-Lex — the links are in the references.
Reading a red yeast rice label outside the EU, including in Korea
None of the above governs a product bought elsewhere. A restriction adopted in Brussels changes what may be sold in the EU, and nothing else.
If you live in Korea, red yeast rice products are available here, and the EU limit and warning text do not apply to them. What you can do is check what a specific product is actually approved to claim and what it declares per serving, in the Food Safety Korea database for health functional food (건강기능식품)[5]. That tells you the approved wording and the declared content, which is the information the EU warnings are built around.
I was not able to verify the current United States regulatory position from a primary source for this article, so I am not going to characterise it. If that matters to your decision, the agency’s own site is the place to check rather than a secondary summary.
There is one point that survives every border, though, because it comes from the chemistry rather than the jurisdiction. If monacolin K is lovastatin, then taking it alongside a prescribed statin means taking more statin than your doctor prescribed, and your doctor does not know. The EU put that on the label. It is true regardless of which label you are holding.
On consumer awareness of certification marks, I looked for reported confusion cases in the public post-market sources this blog uses in place of user reviews. I did not find a dataset that records mark-recognition or confusion for this ingredient. The adverse event systems record suspected harms, which are not confirmed to be caused by the product, and they do not capture whether a shopper understood what a mark meant[6].
Key Terms
- Monacolin K — the compound in red yeast rice at the centre of this story. In lactone form it is identical to lovastatin.
- Lovastatin — a statin, sold in the EU as a prescription medicine for high cholesterol.
- Rhabdomyolysis — a severe breakdown of muscle tissue that can release proteins damaging to the kidneys.
- Union scrutiny — an EU holding status for a substance under suspicion, during which parties may submit data to establish its safety.
- Health claim — wording a label is legally permitted to use about an effect on the body. Permitted claims sit on a Union list.
If this is already on your shelf
Nothing here says red yeast rice does nothing. The awkwardness is the opposite: the reason EFSA took it seriously is that it contains a compound that plainly does something, at doses that overlap with a medicine.
So the practical position is fairly clear. If you take a prescribed statin or any other cholesterol medication, red yeast rice is not a supplement to add quietly — it is a second dose of the same class, and that is a conversation with your doctor. The EU’s other exclusions are a reasonable checklist wherever you live: pregnancy, breastfeeding, under 18, over 70.
And if you are taking it precisely because you would rather not be on a statin, it is worth sitting with what the assessment found. The thing you are taking instead of a statin is, chemically, a statin — with less control over the dose and no one monitoring your liver.
Next in this series: how to read the declared content on a cholesterol supplement label and what the numbers are measured against.
At a Glance
- Monacolin K in lactone form is identical to lovastatin, a prescription statin in the EU[1]
- EFSA concluded in 2018 that supplement intakes could reach therapeutic lovastatin exposures, that 10 mg/day was of significant safety concern, and that severe reactions had been reported as low as 3 mg/day[1]
- EFSA could not identify any intake of monacolins from red yeast rice free of health concerns[1]
- Since 22 June 2022, EU products must provide less than 3 mg of monacolins per daily portion and carry four warnings[2]
- One required warning is not to combine it with cholesterol-lowering medication[2]
- In July 2024 the EU deleted the LDL-cholesterol health claim for red yeast rice from the permitted list[3]
- In February 2025 EFSA found the data submitted during scrutiny did not establish safety below 3 mg/day[4]
- These rules govern products sold in the EU only; check the local database for a product bought elsewhere[5]
※ This article is for information only and does not replace medical diagnosis or treatment. It does not judge or rank any product or brand. Do not start, stop or change any cholesterol medication on the basis of an article. If you take a statin or any other prescribed medication, speak with your doctor before using a red yeast rice product. EU law is amended over time — verify the current consolidated text before relying on any figure here.
References
- EFSA ANS Panel, “Scientific opinion on the safety of monacolins in red yeast rice”, EFSA Journal 2018;16(8):e05368 (indexed in PubMed), https://doi.org/10.2903/j.efsa.2018.5368
- Commission Regulation (EU) 2022/860 of 1 June 2022 amending Annex III to Regulation (EC) No 1925/2006 as regards monacolins from red yeast rice, EUR-Lex, https://eur-lex.europa.eu/eli/reg/2022/860/oj/eng
- Commission Regulation (EU) 2024/2041 of 29 July 2024 amending Regulation (EU) No 432/2012 as regards the health claim on monacolin K from red yeast rice, EUR-Lex, https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX%3A32024R2041
- EFSA NDA Panel, “Scientific Opinion on additional scientific data related to the safety of monacolins from red yeast rice submitted pursuant to Article 8(4) of Regulation (EC) No 1925/2006”, EFSA Journal 2025;23(2):e9276 (indexed in PubMed), https://doi.org/10.2903/j.efsa.2025.9276
- Food Safety Korea (MFDS), “Health Functional Food Search” (product-level approved claims and declared content), https://www.foodsafetykorea.go.kr/portal/healthyfoodlife/searchHomeHF.do
- openFDA, “Food Adverse Event Reports (CAERS) API”, https://open.fda.gov/apis/food/event/